Clinical Trials Directory

Trials / Unknown

UnknownNCT05757297

Gut Microbiota in Patients With Peripheral Arterial Disease and Chronic Limb-threatening Ischemia

Gut Microbiota and Failure of Endovascular Revascularization in Diabetic Patients With Peripheral Arterial Disease and Chronic Limb-threatening Ischemia

Status
Unknown
Phase
Study type
Observational
Enrollment
130 (estimated)
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Microbiota has been associated with risk factors for cardiovascular diseases (hypertension, obesity, dyslipidemia, diabetes mellitus, heart failure). In animal models, the gut microbiota produces pro-inflammatory proteoglycans that increase the extent of myocardial infarction, reduced by treatment with probiotics (Lactobacillus). TMAO, a blood metabolite directly dependent on the gut microbiota is related to atherosclerotic plaque instability and major adverse cardiovascular events (MACE) in humans. Recent data demonstrate that blood levels of TMAO directly correlate with the risk of major MACE and mortality in patients with peripheral arterial disease (PAD). The goal of this observational study is to evaluate the association between gut microbiota and TMAO serum levels and MACE and major adverse limb events (MALE) in patients with PAD and chronic limb threatening ischemia (CLTI) requiring a procedure of endovascular revascularization. The main questions it aims to answer are: * association between gut microbiota and TMAO serum levels and MALE after lower extremity revascularization. * association between gut microbiota and TMAO serum levels and MACE after lower extremity revascularization. Patients with CLTI requiring lower extremity endovascular revascularization will undergo stool sampling for determination of gut microbiota and blood sampling for the dosage of circulating TMAO before the endovascular procedure. Incidence of MALE and MACE will be collected in a 24-months follow-up and will be associated with gut microbiota and TMAO serum levels.

Conditions

Timeline

Start date
2023-03-01
Primary completion
2025-10-31
Completion
2025-10-31
First posted
2023-03-07
Last updated
2023-03-07

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT05757297. Inclusion in this directory is not an endorsement.